Raghav Chari - Dr Reddys Senior Vice President - Proprietary Products
RDY Stock | USD 70.92 0.57 0.80% |
President
Dr. Raghav Chari is Executive Vice President and Head Proprietary Products of Dr. Reddy Laboratories Ltd. He was SENIOR VICEPRESIDENT PROPRIETARY PRODUCTS of the company. He heads Proprietary Products segment and is responsible for developing a viable portfolio of products across Company New Chemical Entities and Differentiated Formulations businesses. Dr. Chari joined the Company in 2006 as Vice President Corporationrationrate Development for Company New Chemical Entities and Specialty business and has helped shape Company Proprietary Products business strategy while developing alliance platforms. He started his career with McKinsey and Company, where he spent several years as an Associate, Engagement Manager and finally Associate Principal in McKinseys Pharmaceuticals and Medical Products practice. After McKinsey, he took leadership roles in strategy and business development with several smaller biotech companies. Prior to joining the Company, he was the head of the Corporationrationrate Strategy function at NPS Pharmaceuticals since 2013.
Age | 45 |
Tenure | 11 years |
Professional Marks | Ph.D |
Address | 8-2-337, Road No. 3, Hyderabad, India, 500034 |
Phone | 91 40 4900 2900 |
Web | https://www.drreddys.com |
Dr Reddys Management Efficiency
The company has Return on Asset of 0.1238 % which means that on every $100 spent on assets, it made $0.1238 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.2139 %, implying that it generated $0.2139 on every 100 dollars invested. Dr Reddys' management efficiency ratios could be used to measure how well Dr Reddys manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is likely to rise to 0.38 in 2024, whereas Return On Tangible Assets are likely to drop 0.11 in 2024. At this time, Dr Reddys' Other Assets are fairly stable compared to the past year. Non Currrent Assets Other is likely to rise to about 15.4 B in 2024, whereas Total Assets are likely to drop slightly above 206.1 B in 2024.Similar Executives
Showing other executives | PRESIDENT Age | ||
Michael Olchaskey | Intracellular Th | N/A | |
Said Saim | Collegium Pharmaceutical | 56 | |
Suresh Durgam | Intracellular Th | N/A | |
Alison Fleming | Collegium Pharmaceutical | 43 | |
Andrew Satlin | Intracellular Th | 62 | |
Rob Aukerman | Phibro Animal Health | 66 | |
Craig Hopkinson | Alkermes Plc | 49 | |
Mark Namchuk | Alkermes Plc | N/A | |
James Jones | Pacira Pharmaceuticals | 51 | |
Anthony Andolino | Phibro Animal Health | 48 | |
Dean Warras | Phibro Animal Health | 48 | |
Shane Cooke | Alkermes Plc | 54 | |
William PPool | Prestige Brand Holdings | 59 | |
Rebecca Peterson | Alkermes Plc | 38 | |
CTodd Nichols | Alkermes Plc | N/A | |
Steven Passik | Collegium Pharmaceutical | N/A | |
Lawrence Hineline | Intracellular Th | 61 | |
Michael Giambalvo | Phibro Animal Health | N/A | |
Samson Li | Phibro Animal Health | 52 | |
Kevin OKeeffe | Collegium Pharmaceutical | N/A | |
John Weet | Collegium Pharmaceutical | N/A |
Management Performance
Return On Equity | 0.21 | ||||
Return On Asset | 0.12 |
Dr Reddys Laboratories Leadership Team
Elected by the shareholders, the Dr Reddys' board of directors comprises two types of representatives: Dr Reddys inside directors who are chosen from within the company, and outside directors, selected externally and held independent of RDY. The board's role is to monitor Dr Reddys' management team and ensure that shareholders' interests are well served. Dr Reddys' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Dr Reddys' outside directors are responsible for providing unbiased perspectives on the board's policies.
MARC KIKUCHI, Chief Executive Officer, North America Generics | ||
Venkata MBA, CEO Council | ||
Leo Puri, Non-Executive Independent Director | ||
Sandeep Poddar, Compliance Officer, Company Secretary | ||
Satish Reddy, Co-Chairman of the Board | ||
Kedar Upadhye, IR Contact Officer | ||
Samiran Das, Executive Vice President Head - FTO and GGPM | ||
Patrick Aghanian, Chief Executive Officer, European Generics | ||
Amit Biswas, Executive Vice President - Integrated Product Development | ||
Ravi Bhoothalingam, Non-Executive Independent Director | ||
Sanjay BTech, Global VP | ||
Prasad Menon, Lead Non-Executive Independent Director | ||
K Rao, Sr. Vice President & Head – Chemical Technical Operations (CTO) | ||
K Krishnan, Additional Independent Director | ||
Shikha Sharma, Non-Executive Independent Director | ||
Omkar Goswami, Non-Executive Independent Director | ||
Bharat Doshi, Non-Executive Independent Director | ||
Gunupati BE, MD CoChairman | ||
Raymond Vre, Global Head of Biologics | ||
Raghav Chari, Senior Vice President - Proprietary Products | ||
Bruce Carter, Non-Executive Independent Director | ||
Umang Vohra, Executive Vice President Head - North America Generics | ||
M Ramana, Chief Executive Officer, Branded Markets (India and Emerging Markets) | ||
Parag Agarwal, Chief Financial Officer - Designate | ||
Cartikeya Reddy, Senior Vice President Head - Biologics | ||
Archana Bhaskar, Chief Human Resource Officer | ||
Erez MBA, CEO Council | ||
MS BTech, Chairman Council | ||
Deepak Sapra, Global Head of Pharmaceutical Services and Active Ingredients | ||
Penny Wan, Additional Independent Director | ||
G Prasad, Co-Chairman of the Board, Chief Executive Officer, Managing Director | ||
P Yugandhar, Global Head of Supply Chain | ||
Hans Hasler, Additional Independent Director | ||
Sauri Gudlavalleti, Global Head of Integrated Product Development Organization | ||
YUGANDHAR PUVVALA, Global Head of Supply Chain | ||
Alok Sonig, Senior Vice President & India Business Head (Generics) | ||
K Singh, Chief Compliance Officer, Company Secretary | ||
Allan Oberman, Non-Executive Independent Director | ||
J Ramachandran, Executive Vice President-Management Systems and Corporate Initiatives | ||
Abhijit Mukherjee, COO | ||
Anil Namboodiripad, Global Head of Proprietary Products | ||
Saumen Chakraborty, President, Chief Financial Officer and Global Head of ITBPE, Legal and Compliance and FMCRE | ||
SANJAY SHARMA, Global Head of Manufacturing | ||
Sridar Iyengar, Non-Executive Independent Director | ||
Ganadhish Kamat, Executive Vice President and Global Head-Quality | ||
Sripada Chandrasekhar, President, Global Head of HR and Member of Management Council | ||
Vivek Mittal, Interim Compliance Officer, General Counsel | ||
Erez Israeli, Chief Operating Officer and Global Head of Generics & PSAI | ||
Kalpana Morparia, Non-Executive Independent Director | ||
J Moreau, Non-Executive Independent Director | ||
Saunak Savla, IR Contact Officer | ||
Deepak MBA, CEO Council | ||
Ashok Ganguly, Non-Executive Independent Director | ||
Anupam Puri, Non-Executive Independent Director | ||
MBA MBA, CEO Council | ||
Mukesh Rathi, Chief Digital and Information Officer |
RDY Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Dr Reddys a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.21 | ||||
Return On Asset | 0.12 | ||||
Profit Margin | 0.19 % | ||||
Operating Margin | 0.25 % | ||||
Current Valuation | (40.79 B) | ||||
Shares Outstanding | 166.53 M | ||||
Shares Owned By Institutions | 15.02 % | ||||
Number Of Shares Shorted | 625.76 K | ||||
Price To Earning | 31.58 X | ||||
Price To Book | 3.70 X |
Currently Active Assets on Macroaxis
When determining whether Dr Reddys Laboratories offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Dr Reddys' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Dr Reddys Laboratories Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Dr Reddys Laboratories Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Dr Reddys Laboratories. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. Note that the Dr Reddys Laboratories information on this page should be used as a complementary analysis to other Dr Reddys' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Complementary Tools for RDY Stock analysis
When running Dr Reddys' price analysis, check to measure Dr Reddys' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dr Reddys is operating at the current time. Most of Dr Reddys' value examination focuses on studying past and present price action to predict the probability of Dr Reddys' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dr Reddys' price. Additionally, you may evaluate how the addition of Dr Reddys to your portfolios can decrease your overall portfolio volatility.
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Stocks Directory Find actively traded stocks across global markets |
Is Dr Reddys' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dr Reddys. If investors know RDY will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dr Reddys listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.103 | Dividend Share 40 | Earnings Share 3.76 | Revenue Per Share 272.4618 | Quarterly Revenue Growth 0.066 |
The market value of Dr Reddys Laboratories is measured differently than its book value, which is the value of RDY that is recorded on the company's balance sheet. Investors also form their own opinion of Dr Reddys' value that differs from its market value or its book value, called intrinsic value, which is Dr Reddys' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dr Reddys' market value can be influenced by many factors that don't directly affect Dr Reddys' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Dr Reddys' value and its price as these two are different measures arrived at by different means. Investors typically determine if Dr Reddys is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dr Reddys' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.